Oragenics, Inc. (OGEN)
After hours:
| Previous Close | 0.3249 |
| Open | 0.3250 |
| Bid | 0.3000 x 1000 |
| Ask | 0.3250 x 2200 |
| Day's Range | 0.3062 - 0.3450 |
| 52 Week Range | 0.2900 - 7.7400 |
| Volume | |
| Avg. Volume | 773,426 |
| Market Cap | 3.435M |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.3300 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireOragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit to be held at the Rosewood Baha Mar Hotel on October 22-23, 2024, in Nassau, Bahamas. Michael Redmond, President of Oragenics, will participate in a corporate presentation and Q&A session on October 22, 2024 at 1:20 pm ET. Details for the pr
- GlobeNewswire
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided a corporate update reflecting on the company’s progress throughout 2024, including key milestones in the development of ONP-002, its lead candidate for the treatment of concussions. Company Overview: A Vision for Innovation in NeurologyOragenics is focused on revolutionizing drug delivery for neurol
